Solid Tumors
Children with solid tumors could be treated by cefixime administered with oral irinotecan
Published in Vaccine Weekly, April 19th, 2006
"Irinotecan is active against a variety of malignancies; however, severe diarrhea limits its usefulness. In our phase I study, the intravenous formulation of irinotecan was administered orally daily for 5 days for 2 consecutive weeks (repeated every 21 days) to children with refractory solid tumors," scientists in the United States reported.
"Our objectives were to determine the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of oral irinotecan and to evaluate whether coadministration of cefixime (8 mg/kg/d beginning 5 days before...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-04-19)
More Articles from Vaccine Weekly
- Chlamydia Vaccine
Chlamydia trachomatis major outer membrane protein induces partial protection - Chronic Viral Infection
In chronic viral infection, blocking antibodies restore function in exhausted CD8 cells - Immunotherapy
Measles, mumps, rubella, and varicella vaccine can replace second-dose vaccinations - Klebsiella Vaccine
Two immunogenic proteins may be potential Klebsiella pneumoniae vaccine candidates - SARS Vaccine
Anti-SARS-CoV immunity is induced by a novel CpG oligodeoxynucleotide - Animal Tuberculosis
Chembio edges closer to entering the $50 million veterinary TB market - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
